References
- Mendel D. B., Laird A. D., Xin X., Louie S. G., Christensen J. G., Li G., Schreck R. E., Abrams T. J., Ngai T. J., Lee L. B., Murray L. J., Carver J., Chan E., Moss K. G., Haznedar J. O., Sukbuntherng J., Blake R. A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J. M. In vivo anti‐tumor activity of SU011248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003; 9(1)327–337
- Allen L. V., Jr., Erickson M. A., III. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Am. J. Health‐Syst. Pharm. 1998; 55(18)1915–1920
- Allen L. V., Jr., Erickson M. A. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids. Am. J. Health‐Syst. Pharm. 1998; 55(17)1804–1809
- Allen L. V., Jr., Erickson M. A., III. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am. J. Health‐Syst. Pharm. 1996; 53(17)2073–2078
- Boonme P., Phadoongsombut N., Phoomborplub P., Viriyasom S. Stability of extemporaneous norfloxacin suspension. Drug Devel. Ind. Pharm. 2000; 26(7)777–779
- Aubry A. F., Sebastian D., Hobson T., Xu J. Q., Rabel S., Xie M., Gray V. In use testing of extemporaneously prepared suspensions of second generation non‐nucleoside reversed transcripts inhibitors in support of Phase I clinical studies. J. Pharm. Biomed. Anal. 2000; 23(200)535–542
- Ho P.‐C., Ghose K., Saville D., Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur. J. Clin. Pharmacol. 2000; 56(9–10)693–698
- Takanaga H., Ohnishi A., Matsuo H., Murakami H., Sata H., Kuroda K., Urae A., Higuchi S., Sawada Y. Pharmacokinetic analysis of felodipine–grapefruit juice interaction based on an irreversible enzyme inhibition model. Br. J. Clin. Pharmacol. 2000; 49(1)49–58